{"id":"W4403285343","doi":"10.1016/j.clon.2024.10.008","title":"Real World Outcomes in Patients With Recurrent, Advanced, or Metastatic Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab","year":2024,"lang":"en","type":"article","venue":"Clinical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Medicine; Pembrolizumab; Lenvatinib; Tolerability; Internal medicine; Oncology; Carcinosarcoma; Endometrial cancer; Population; Cancer; Adverse effect; Carcinoma; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005298425,0.0001589383,0.0004219893,0.0002809611,0.0002776953,0.001032491,0.000239028,0.0004079727,0.001618601],"category_scores_gemma":[0.003655802,0.0001014994,0.0008455822,0.0005352591,0.0002554427,0.0007016627,0.0005082919,0.0007661763,0.0001881425],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009276359,"about_ca_system_score_gemma":0.0004397863,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003812321,"about_ca_topic_score_gemma":0.006135364,"domain_scores_codex":[0.9995762,0.0001522737,0.0000475815,0.00006851148,0.00005051638,0.0001049709],"domain_scores_gemma":[0.998634,0.0002751572,0.0006764364,0.00004658424,0.00009937449,0.0002683605],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00730655,0.0002892983,0.9641131,0.0001922599,0.001351002,0.0004612431,0.0002089548,0.001660499,0.0003036001,0.0002582266,0.002496368,0.02135889],"study_design_scores_gemma":[0.000316224,0.001885363,0.9897215,0.00009480244,0.0008424653,0.0008188083,0.000602445,0.001957093,0.0001730908,0.0004421702,0.003107043,0.00003912279],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9936141,0.001954462,0.0001048895,0.0005212653,0.00004843928,0.0000166189,0.00181645,0.000005492297,0.001918216],"genre_scores_gemma":[0.9978926,0.0003470427,0.00004568183,0.00009655343,0.00003183943,0.00001139998,0.001409449,0.00000186703,0.0001635811],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003812321,"threshold_uncertainty_score":0.007580221,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.106635617466079,"score_gpt":0.4543742902599759,"score_spread":0.3477386727938969,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}